Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) FCF Margin (2017 - 2025)

Crinetics Pharmaceuticals has reported FCF Margin over the past 9 years, most recently at 1600.49% for Q4 2025.

  • Quarterly results put FCF Margin at 1600.49% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 4985.5% (up 1718717.0% YoY), and the annual figure for FY2025 was 4985.5%, up 1718717.0%.
  • FCF Margin for Q4 2025 was 1600.49% at Crinetics Pharmaceuticals, up from 77404.2% in the prior quarter.
  • Over the last five years, FCF Margin for CRNX hit a ceiling of 432.55% in Q1 2022 and a floor of 77404.2% in Q3 2025.
  • Median FCF Margin over the past 5 years was 7338.17% (2022), compared with a mean of 12454.06%.
  • Peak annual rise in FCF Margin hit 416213bps in 2025, while the deepest fall reached -1629007bps in 2025.
  • Crinetics Pharmaceuticals' FCF Margin stood at 2125.88% in 2021, then tumbled by -144bps to 5190.83% in 2022, then plummeted by -151bps to 13021.1% in 2023, then grew by 4bps to 12471.93% in 2024, then skyrocketed by 87bps to 1600.49% in 2025.
  • The last three reported values for FCF Margin were 1600.49% (Q4 2025), 77404.2% (Q3 2025), and 8309.8% (Q2 2025) per Business Quant data.